Zai Lab Plans to Seek Efgartigimod Approval in China in Early 2022
Zai Lab is planning — in the first half of 2022 — to ask Chinese authorities to approve efgartigimod (ARGX-113) as a treatment for generalized myasthenia gravis (gMG) in that country. The therapy, being developed by Argenx and designed to lessen the body’s immune attacks against…